Novo Nordisk chair, board members to quit
Digest more
The overhaul comes after the foundation ousted former chief executive Lars Fruergaard Jørgensen in May, blaming him for an ...
Sure, Eli Lilly’s Tirzepatide-based drugs have caught up significantly to Novo Nordisk’s semaglutide-based ones. As a result, ...
Novo Nordisk's top investor moved to take control of the drugmaker's board on Tuesday, vowing a sharper focus on the key U.S.
A major boardroom shake-up at Novo Nordisk has given the Novo Nordisk Foundation an unprecedented level of control, raising ...
Get the latest on Novo Nordisk's Alzheimer's trial, stock outlook, and market risks. See what investors need to know before ...
Another week, another twist in the turnaround efforts at Novo Nordisk, the maker of the blockbuster Ozempic and Wegovy weight ...
With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...
While Novo Nordisk has been victimized by broader market pressure, NVO stock has just flashed a reliable quant signal for ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback